ARCHIVES

Bristol Stock Drops Amid New Setbacks, Deepening Firm’s Decline In Oncology

This article is from The Cancer Letter archive.

Vol. 28 No. 14 | April 5, 2002

Download PDF Visit The Full Archive

Related Articles

Major Emphasis Switch; Outreach Core Support Ends In Favor Of Cancer Control Research

January 22, 1982

FDA Approves Afinitor For pNET; No Word On Sutent For Same Use

May 6, 2011

JR Adams Elected President, Ovarian Cancer Coalition.

March 9, 2001

“Mini-Transplantation” In Testing For Treatment Of Multiple Myeloma

January 25, 2002

Gramm-Rudman Cut Facing NCI Could Take $85 Million

October 20, 1989

Three Organizations Publish Guideline For Biomarker Testing for Targeted Therapies

April 26, 2013